#238 – AMA #43: Understanding apoB, LDL-C, Lp(a), and insulin as risk factors for cardiovascular disease

Jan 16, 2023 Episode Page ↗
Overview

In this AMA episode, Dr. Peter Attia and Nick Stenson discuss atherosclerotic cardiovascular disease (ASCVD), its risk factors like apoB, Lp(a), and hyperinsulinemia, and their interrelation. They explore how metabolic dysfunction contributes to residual ASCVD risk and the importance of early prevention.

At a Glance
6 Insights
24m 23s Duration
5 Topics
6 Concepts

Deep Dive Analysis

Understanding ASCVD Risk with a Race Car Analogy

Differentiating ApoB, LDL-C, and LDL-P Measurements

Hyperinsulinemia's Impact on ASCVD Risk via ApoC3

Hyperinsulinemia's Role in Endothelial Dysfunction

Using the Oral Glucose Tolerance Test (OGTT) for Insulin Levels

LDL-C

LDL-C is a laboratory measurement that quantifies the concentration of cholesterol contained within low-density lipoprotein (LDL) particles. While it predicts ASCVD risk, it is considered less comprehensive than ApoB.

ApoB

ApoB (apolipoprotein B) measures the concentration of all particles that carry the ApoB lipoprotein, which includes LDL, VLDL, and Lp(a). It is a better predictor of ASCVD risk than LDL-C because it captures the total number of atherogenic particles, not just the cholesterol within them.

ApoC3

ApoC3 (apolipoprotein C3) is a lipoprotein whose increased expression, often linked to hyperinsulinemia and insulin resistance, blocks the activation of lipoprotein lipase (LPL). This blockage leads to higher triglyceride levels and an increase in triglyceride-rich LDLs, ultimately raising ApoB concentration and ASCVD risk.

Lipoprotein Lipase (LPL)

LPL is an enzyme located on cells that plays a crucial role in controlling lipolysis, the breakdown of fats. When its activity is inhibited, such as by elevated ApoC3, it results in reduced utilization of triglycerides and an increase in their circulating concentration.

Endothelial Dysfunction

Endothelial dysfunction refers to the impaired functioning of the endothelium, the inner lining of blood vessels. This dysfunction makes it easier for ApoB particles to penetrate the subendothelial space, contributing to the initiation and progression of atherosclerotic cardiovascular disease, and hyperinsulinemia appears to drive this process.

Oral Glucose Tolerance Test (OGTT)

The OGTT is a diagnostic test used to assess how well the body processes glucose and insulin. It is particularly useful for identifying hyperinsulinemia in a postprandial state, where glucose levels may be normal but insulin levels are elevated, indicating early insulin resistance.

?
What analogy can help understand atherosclerotic cardiovascular disease (ASCVD) risk factors?

ASCVD risk can be understood as driving a race car towards a cliff (death), where factors like Lp(a) and hyperinsulinemia act as the 'throttle' accelerating progress, and lowering ApoB acts as the 'brake' slowing it down.

?
What is the difference between LDL-C and ApoB?

LDL-C measures the concentration of cholesterol within LDL particles, while ApoB measures the concentration of all particles carrying the ApoB lipoprotein (including LDL, VLDL, and Lp(a)), making ApoB a better predictor of ASCVD risk as it reflects the number of atherogenic particles.

?
How do insulin levels relate to other lipid and ASCVD parameters like ApoB?

Hyperinsulinemia is unequivocally associated with worse ASCVD outcomes, primarily by increasing ApoC3 expression which blocks lipoprotein lipase, leading to higher triglycerides and triglyceride-rich LDLs, thereby increasing ApoB concentration.

?
How does hyperinsulinemia contribute to ASCVD risk beyond its effects on lipids?

Hyperinsulinemia also appears to drive endothelial dysfunction, making it easier for ApoB particles to penetrate the subendothelial space and initiate the inflammatory cascade that propagates ASCVD.

?
How can someone assess their insulin levels if they don't have type 2 diabetes?

An Oral Glucose Tolerance Test (OGTT) can reveal hyperinsulinemia, especially in a postprandial state, where glucose levels remain normal but insulin levels are elevated, serving as an early indicator of insulin resistance.

1. Prioritize Early Risk Intervention

Address atherosclerotic cardiovascular disease (ASCVD) risk factors like ApoB, hyperinsulinemia, smoking, and hypertension early in life, as prompt action allows for more effective interventions and slows disease progression.

2. Monitor ApoB Over LDL-C

Prioritize measuring and monitoring ApoB concentration over LDL-C for assessing ASCVD risk, as ApoB is a better predictor that captures all atherogenic particles and serves as a key goalpost for risk reduction.

3. Detect Hyperinsulinemia Early

Look for postprandial hyperinsulinemia, characterized by elevated insulin 30-60 minutes after a glucose challenge, as a “canary in the coal mine” for early insulin resistance and increased ASCVD risk, even if fasting glucose is normal.

4. Utilize Oral Glucose Tolerance Test

Consider undergoing an Oral Glucose Tolerance Test (OGTT) to assess your postprandial insulin levels, which can help detect early insulin resistance and provide insight into your current metabolic state, even if you don’t have type 2 diabetes.

5. Actively Manage ASCVD Drivers

Focus on actively lowering high blood pressure, ceasing smoking, and reducing ApoB levels, as these are identified as the three primary and most impactful drivers of atherosclerotic cardiovascular disease (ASCVD).

6. Understand Lp(a) Baseline Risk

Recognize that Lp(a) levels are largely genetically determined and not directly modifiable, serving as a “low level of maintenance throttle” that contributes to baseline ASCVD risk.

your lifespan is the length of time it takes you to drive a race car from point a to point b where point b is driving it off a cliff and you have two feet and two pedals right so you have the accelerator and you have the brake and your feet are always on both pedals so it's really just a question of how hard are you pressing on each one

Peter Attia

the more you're lowering apob the harder you're pushing on the brake

Peter Attia

apob is a better predictor of risk because it captures not only the concentration of ldl and we know that it's the number of particles more than the cholesterol concentration of the particles that drives risk but also because it includes the other atherogenic particles namely the vldl

Peter Attia

the observation that is unequivocal is hyperinsulinemia is associated with worse outcomes in ascvd

Peter Attia

the true canary in the coal mine is it's a postprandial challenged glucose response where glucose is normal but insulin is distorted insulin is elevated

Peter Attia